A new study reveals that individuals younger than 50 years of age who are diagnosed with rectal cancer do not experience an overall survival benefit from currently recommended treatments. Specifically, the addition of chemotherapy and radiation to surgery does not prolong life for these patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that early onset disease may differ from later onset disease in terms of biology and response to therapy.
The overall incidence of rectal cancer is decreasing in patients older than 50 years of age, likely due to improved screening adherence; however, there is a disproportionate increase in rectal cancer incidence in patients under the age of 50 years. In addition, the mortality rate from rectal cancer among younger patients has increased in the past several decades.
Current national guidelines--which recommend a combination of chemotherapy, radiation, and surgery for stages II and III rectal cancer--are predominantly based on data from patients older than 50 years of age. To examine how younger patients fare, a team led by Atif Iqbal, MD, of the University of Florida College of Medicine, in Gainesville, examined 2004-2014 information from the National Cancer Database. A total of 52,519 patients were analyzed.
The team found that patients younger than 50 years old who have been diagnosed with rectal cancer represent a unique group. These younger patients do not see a survival benefit from receiving the currently recommended treatment for stages II and III rectal cancer.
"Our findings support the notion that rectal cancer in young patients may be biologically different from older patients, with differing response to treatment, as has been previously shown in colon cancer," said Dr. Iqbal. "These findings may help stimulate future research trial proposals focused on the younger patient population."
The study also reveals age-specific survival data for younger patients. "These data provide practicing physicians the ability to offer a prognosis personalized to the younger population, which can greatly improve discussions with younger patients."
In an accompanying editorial, Matthew Kalady, MD, of the Cleveland Clinic notes that the findings highlight the need to continually evaluate approaches to colorectal cancer prevention, screening, and treatment. "This manuscript should open the eyes of physicians treating rectal cancer patients and of those making treatment guideline recommendations and screening policies," he wrote. He noted that the study did not address other clinically important endpoints for rectal cancer patients such as local recurrence and disease-free survival. He added that studies are needed to evaluate how factors such as diet, physical activity and obesity, underlying genetics, and gut microbes may interact with rectal cancer biology.
###
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the Cancer News Room upon online publication. For more information or to obtain a PDF of any study, please contact:
Dawn Peters (US) +1 781-388-8408
sciencenewsroom@wiley.com
Follow us on Twitter @WileyNews
Full Citations:
"Rectal cancer patients under 50 years of age lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease." Andrew Kolarich, Thomas J. George, Jr, Steven J. Hughes, Daniel Delitto, Carmen J. Allegra, William A. Hall, George J. Chang, Sanda A. Tan, Christiana M. Shaw, and Atif Iqbal. CANCER; Published Online: July 9, 2018 (DOI: 10.1002/cncr.31527).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.31527
"Rectal Cancer in Young Patients: Time to Take Notice." Matthew Kalady. CANCER; Published Online: July 9, 2018 (DOI: 10.1002/cncr.31524).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.31524
Author Contact: Marilee Griffin, of the UF Health Communications office, at margri@ufl.edu.
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.
Follow us on Twitter @JournalCancer
About Wiley
Wiley, a global research and learning company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 210 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.
Journal
Cancer